#Bioretec #Finland #Tampere #Annual Meeting #Board Members

Bioretec Ltd. Shareholders' Nomination Board Proposals

On January 30, 2026, the Shareholders' Nomination Board of Bioretec Ltd announced its proposals for the upcoming Annual General Meeting (AGM) set for May 8, 2026. This announcement showcases the organization’s commitment to governance and transparency in its operations.

Remuneration Proposals

The Nomination Board has proposed a remuneration structure for the Board members for the term ending at the next AGM in 2027. The details of this proposal include:

• - Chairperson of the Board: €3,750 per month (same as 2025)
• - Deputy Chairperson of the Board: €2,500 per month (same as 2025), conditional upon the election of a Deputy Chairperson to assist with succession planning
• - Board Members: €2,000 per month (same as 2025)

In addition to monthly remuneration, the Board members' reasonable travel expenses will be reimbursed based on the Tax Administration's approved allowances. This structure reflects Bioretec's focus on fair compensation while ensuring efficiency and accountability.

Board Composition Proposal

The Nomination Board also proposed that a total of six members be elected to the Board of Directors. Previously, the board consisted of six members; however, one member stepped down following a transition to a different role within the organization. This election will replenish the board following prior vacancies and aims to maintain the strength and diversity of expertise at the company’s leadership level.

Elections of Current and New Board Members

The Nomination Board has recommended the re-election of four existing members:
1. Michael Piccirillo, B.Sc. Microbiology, BBA
2. Päivi Malinen, LL.M
3. Kustaa Poutiainen, M.Sc. (Econ)
4. Antti Vasara, Doctor of Science (Technology)
5. Additionally, Justin Barad, MD will also be re-elected as a Board member.
6. A new addition, David Gill, MBA, BS, has been suggested as a fresh face to bring new perspectives to the Board.

These proposed members have been assessed for independence, resulting in all being deemed independent of Bioretec, with the exception of Kustaa Poutiainen, who has connections with a major shareholder but is still considered independent of the company.

Emphasis on Diversity and Expertise

In formulating these proposals, the Nomination Board emphasized the importance of board diversity, ensuring that candidates bring a wealth of experience and knowledge crucial for Bioretec's future success. The process followed by the Nomination Board prioritizes the overall expertise and experience required for effective governance while upholding the principles of independence.

Composition of the Nomination Board

The composition of the Shareholders' Nomination Board consists of:

• - Tor-Oskar Karlberg (Stephen Industries Inc Oy, Chair)
• - Rami Vehmas (Ilmarinen Mutual Pension Insurance Company)
• - Heinz Moitzi (WM GmbH)

Kustaa Poutiainen acts as an expert alongside the Nomination Board, providing valuable insights into the selection process, ensuring that Bioretec’s strength in governance is upheld.

Looking Forward

The Bioretec AGM will cover vital aspects of the company's governance, reinforcing the importance of shareholder engagement in the decision-making processes that guide the firm's trajectory. Detailed presentations of current board members and potential new recruits are available on Bioretec's investor relations site.

Bioretec is recognized globally for its innovations in orthopedic care through biodegradable implants. With a focus on enhancing recovery and surgical effectiveness, the board selections will play a critical role in continuing this mission. Stakeholders are encouraged to engage with the nomination process, contributing to the future direction of Bioretec.

For further inquiries, Tor-Oskar Karlberg, the Chairperson of the Nomination Board, may be contacted directly.

Visit Bioretec’s official site for more information on their pioneering medical technologies.